

# Criteria Based Consultation Prescribing Program

## CRITERIA FOR DRUG COVERAGE

### Transmucosal Immediate-Release Fentanyl Products (TIRFs)

Non-formulary **transmucosal immediate-release fentanyl products** [Actiq<sup>®</sup> (and its generics), Fentora<sup>®</sup>, Onsolis<sup>®</sup>, Abstral<sup>®</sup>, Lazanda<sup>®</sup>, and Subsys<sup>®</sup>)] will be covered on the prescription drug benefit when the following criteria are met:

- **Diagnosis of cancer on problem list**  
- AND -
- **Over 18 years old**  
- AND -
- **Already receiving and tolerant to around-the-clock opioid therapy of at least 60 mg of morphine daily (or equivalent)^**  
- AND -
- **Documented treatment failure after an adequate trial of morphine immediate-release (IR) AND oxycodone IR AND hydromorphone IR or allergy or intolerance to morphine AND oxycodone AND hydromorphone**  
- AND -
- **Prescribed by or after consultation with Pain Management, ONC or Hospice/Palliative Care clinician**  
- AND -
- **Prescriber has completed Risk Evaluation Mitigation Strategy (REMS) training and enrollment. The Transmucosal Immediate-Release Fentanyl (TIRF) products can only be dispensed through the SYB pharmacy after prescriber has enrolled in the TIRF REMS Access program.**  
- OR -
- **Dose Change Only: Patient previously met criteria and is already taking the drug, and the prescriber is already enrolled in the TIRF REMS Access Program.**

^daily dose of at least 60 mg of morphine or 30 mg of oxycodone or 8 mg of hydromorphone or 25 mg of oxymorphone or 25 mcg/hr transdermal fentanyl